

02-15-06

JPM

Attorney Docket No.: 9310-151

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Sillekens

Application No.: 10/559,949

Filed: December 9, 2005

For: *NUCLEIC ACID SEQUENCES THAT CAN BE USED AS PRIMERS AND PROBES IN THE AMPLIFICATION AND DETECTION OF SARS CORONAVIRUS*

Date: February 14, 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)**

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

Respectfully submitted,

Mary L. Miller
Mary L. Miller
Registration No. 39,303

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792


CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

"Express Mail" mailing label number: EV675784382US

Date of Deposit: February 14, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Tracy Wallace
Tracy Wallace



Application Number	10/559,949
Filing Date	December 9, 2006
First Named Inventor	Sillekens.
Group Art Unit	
Examiner Name	
Attorney Docket Number	9310-151

[illegible]

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
J.T./	4.	Zhou et al. 2003. "One-step duplex RT-PCR assay for detection SARS associated coronavirus" <i>VIROLOGICA SINICA</i> 18:232-236 (English abstract only)	
	5.	Yang et al. 2003. "Clinical detection of polymerase gene of SARS-associated coronavirus" <i>Academic Journal of the First Military Medical University</i> 23:424-427 (English abstract only)	
	6.	Drosten et al. 2003. "Identification of a novel coronavirus in patients with severe acute respiratory syndrome" <i>New England Journal of Medicine</i> 348:1967-1976	
	7.	Shi et al. 2003. "Design and application of 60mer oligonucleotide microarray in SARS coronavirus detection" <i>Chinese Science Bulletin</i> 48:1165-1169.	
	8.	Kim et al. 2001. "Cloning and characterization of novel genes related with the development of rat brain" <i>EMBL Database Accession No. AT005537</i> .	
	9.	Deiman et al. 2002. "Characteristics and applications of nucleic acid sequence-based amplification (NASBA)" <i>Molecular Biotechnology</i> 20:163-179.	
	10.	Ksiazek et al. 2003. "A novel coronavirus associated with severe acute respiratory syndrome" <i>New England Journal of Medicine</i> 348:1953-1966.	
J.T./	11.	Copy of International Search Report for PCT Application No. PCT/EP2004/002553, mailed January 12, 2004.	

11/23/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.